Affimed NV Company Profile (NASDAQ:AFMD)

About Affimed NV (NASDAQ:AFMD)

Affimed NV logoAffimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AFMD
  • CUSIP: N/A
  • Web:
  • Market Cap: $94.47 million
  • Outstanding Shares: 43,938,000
Average Prices:
  • 50 Day Moving Avg: $2.16
  • 200 Day Moving Avg: $2.19
  • 52 Week Range: $1.65 - $2.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.69
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.99 million
  • Price / Sales: 23.68
  • Book Value: $1.10 per share
  • Price / Book: 1.95
  • EBITDA: ($36,260,000.00)
  • Net Margins: -1,564.37%
  • Return on Equity: -72.67%
  • Return on Assets: -57.82%
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 6.69%
  • Quick Ratio: 6.65%
  • Average Volume: 252,318 shs.
  • Beta: 3.65
  • Short Ratio: 2.6

Frequently Asked Questions for Affimed NV (NASDAQ:AFMD)

What is Affimed NV's stock symbol?

Affimed NV trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed NV's earnings last quarter?

Affimed NV (NASDAQ:AFMD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. The firm earned $0.51 million during the quarter, compared to analysts' expectations of $1.31 million. Affimed NV had a negative return on equity of 72.67% and a negative net margin of 1,564.37%. The company's revenue was down 75.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) earnings per share. View Affimed NV's Earnings History.

When will Affimed NV make its next earnings announcement?

Affimed NV is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Affimed NV.

Where is Affimed NV's stock going? Where will Affimed NV's stock price be in 2017?

4 analysts have issued 1 year price targets for Affimed NV's shares. Their forecasts range from $2.00 to $10.00. On average, they expect Affimed NV's stock price to reach $5.38 in the next year. View Analyst Ratings for Affimed NV.

Are investors shorting Affimed NV?

Affimed NV saw a decrease in short interest in September. As of September 29th, there was short interest totalling 409,062 shares, a decrease of 42.6% from the September 15th total of 712,056 shares. Based on an average daily volume of 386,134 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.5% of the company's shares are sold short.

Who are some of Affimed NV's key competitors?

How do I buy Affimed NV stock?

Shares of Affimed NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affimed NV's stock price today?

One share of Affimed NV stock can currently be purchased for approximately $2.15.

MarketBeat Community Rating for Affimed NV (NASDAQ AFMD)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about Affimed NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Affimed NV (NASDAQ:AFMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.38 (150.00% upside)
Consensus Price Target History for Affimed NV (NASDAQ:AFMD)
Price Target History for Affimed NV (NASDAQ:AFMD)
Analysts' Ratings History for Affimed NV (NASDAQ:AFMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Jefferies Group LLCReiterated RatingHold$2.50LowView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$7.00HighView Rating Details
5/18/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$10.00LowView Rating Details
11/3/2016Leerink SwannReiterated RatingHold$2.00N/AView Rating Details
5/18/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$7.00N/AView Rating Details
12/10/2015LaidlawInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Affimed NV (NASDAQ:AFMD)
Earnings by Quarter for Affimed NV (NASDAQ:AFMD)
Earnings History by Quarter for Affimed NV (NASDAQ AFMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/20176/30/2017($0.22)($0.20)$1.31 million$0.51 millionViewListenView Earnings Details
5/17/20173/31/2017($0.24)($0.21)$1.73 million$1.94 millionViewN/AView Earnings Details
3/30/201712/31/2016($0.31)($0.17)$1.20 million$1.37 millionViewN/AView Earnings Details
11/2/2016Q316($0.26)($0.31)$2.65 million$0.94 millionViewN/AView Earnings Details
8/10/2016Q216($0.22)($0.24)$2.10 million$2.07 millionViewListenView Earnings Details
5/18/2016Q116($0.15)($0.25)$1.88 million$1.90 millionViewListenView Earnings Details
3/30/2016Q415($0.18)($0.19)$1.71 million$1.66 millionViewListenView Earnings Details
11/10/2015Q315($0.25)($0.27)$1.87 million$1.20 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.21)$2.56 million$2.21 millionViewN/AView Earnings Details
5/21/2015Q115($0.14)($0.07)$4.75 million$2.82 millionViewListenView Earnings Details
3/25/2015Q414($0.39)($0.24)$0.89 million$0.09 millionViewN/AView Earnings Details
11/18/2014Q314($0.33)$2.69$0.89 million$2.35 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Affimed NV (NASDAQ:AFMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.21)($0.18)($0.20)
Q3 20174($0.22)($0.19)($0.20)
Q4 20173($0.24)($0.18)($0.21)
(Data provided by Zacks Investment Research)


Dividend History for Affimed NV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Affimed NV (NASDAQ:AFMD)
No insider trades for this company have been tracked by


Headline Trends for Affimed NV (NASDAQ:AFMD)
Latest Headlines for Affimed NV (NASDAQ:AFMD)
Loading headlines, please wait.



Affimed NV (AFMD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.